ISLA-101

Island's lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever. Around 390 million people are infected with dengue fever each year[1], representing a significant unmet need and opportunity. SYDNEY, May 19, 2021 /PRNewswire/ -- Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to announce that a key patent relating to the Company's lead program, ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses. The US patent grant was issued on 18 May 2021 (US time) under US Patent No US 11,007,160 and has an expiration date of 16 April 2034. Island has licensed the IP portfolio, generated by Monash University. Executive Chairman of Island, Dr Paul MacLeman commented, "The grant of the US patent is a significant development for Island Pharmaceuticals. Mosquito borne viruses, such as dengue, Zika and others represent major unmet medical needs throughout the world and about 3 billion people – or 40% of the world's population – live in areas with a risk of dengue[2]. Having an allowed patent that protects Island's lead program in this large market provides protection for the development of ISLA-101 and further underpins our ability to advance the program in the US – a key target market." Dengue fever is often seen as predominantly a disease of developing countries. However, global warming has meant that mosquitoes carrying dengue are travelling further, and in the last few years, rising case numbers have been recorded in Florida and, as recently as 2019, in North Queensland. Hundreds of cases per annum have been seen in recent years in FIFO workers in West Australian mines. Dengue is endemic in much of Asia, the South Pacific, South America, Central America and Africa. Around 390 million humans are infected each year, representing a significant unmet need and opportunity. About Island Pharmaceuticals (ASX: ILA) Island is clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects. If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) will permit Island to expedite the FDA approval process for a new drug, or sell the PRV in a secondary market. Recent transactional benchmarking suggests that PRVs attract US$75m-$150m. Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website. Visit for more info. Company Codes: Australia:ILA

Investments towards research of live attenuated vaccines for mosquito-borne disease treatments in major population centers is generating better prospects for sales. Fact.MR Rockville, MD: An ongoing report on the mosquito-borne disease treatments market by market research firm Fact.MR has projected positive growth prospects for 2021. The covid-19 pandemic has moderately impacted the industry owing to the redirection of healthcare facilities towards the new threat of the coronavirus. However, continued concerns over vector-borne disease is expected to sustain steady growth in the market in the coming years. According to the World Mosquito Program, close to 700 million people globally contract mosquito borne ailments annually, which results in approximately a million deaths. In recent years, dengue cases have risen strongly and 40 percent of the global population is considered to be at risk, with around 25,000 patients succumbing to the disease annually. Malaria continues to be a major contributor to the market, with 300 to 500 million cases being reported annually. Further, diseases such as arboviral encephalitides and dog heartworm are likely to create lucrative opportunities for manufacturers, owing to risk of infection among animals as well. “Increasing investments towards research and development activities for new drugs and combinations have arisen owing to cases of resistance by parasites to the currently available drug portfolios. This is a key factor anticipated to drive the global mosquito-borne diseases treatment market,” comments a Fact.MR analyst. Request a report sample to gain detailed insights at Key Takeaways from Fact.MR’s Mosquito-borne Diseases Treatments Market Japanese encephalitis and West Nile virus treatments to gain impetus driven by treatment development initiatives. Antiviral drugs to display relatively higher demand, owing to higher incidences of associated diseases in emerging economies. Retail pharmacies will remain popular distribution channels owing to better accessibility for patients. Major drug development efforts by leading players keeps the US at the forefront of the mosquito-borne disease treatment market. China and India are displaying high potential for growth owing to government initiatives towards healthcare spending and infectious disease prevention. France and Spain are key markets supported by higher awareness and diagnostic testing. Mosquito-borne Diseases Treatment Market – Prominent Drivers Increased funding by regional governments towards research is a key contributor to market growth. Collaborative efforts by market players towards the development of novel treatment approach creates opportunities in the industry. Growth of high-density population centers has increased risk of transmission, generating market growth opportunities. Mosquito-borne Diseases Treatment Market – Key Restraints Lack of adequate expertise on the pathophysiology of mosquito borne diseases a challenge for market players. Symptoms of multiple mosquito borne diseases are similar creating challenges in terms of diagnosis and subsequently the treatment. Discover more about the mosquito-borne disease treatments market with figures data tables and table of contents. You can also find detailed market segmentation at Competitive Landscape Major players in the mosquito-borne diseases treatment market include but are not limited to Lupin Inc., Sanofi SA, GlaxoSmithKline plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Merck & Co. Inc., Novartis AG, and Johnson & Johnson. Investments into research for repurposing drugs for new treatments are gaining traction among manufacturers. For example, In Oct 2020, U.S.-based Isla pharmaceuticals has announced the patent approval of the company’s repurposed Isla 101 molecular offering by the Brazilian Industrial Property Office for preventing and treating mosquito borne diseases. Manufacturers are also displaying increased interest in strategic collaborations within the industry aimed towards product research and development. ConserV Bioscience Ltd. has entered into a collaboration with eTheRNA Immunotherapies for the development of mRNA vaccines for infectious ailments including mosquito-borne diseases in March 2021. More Insights on the Mosquito-borne Diseases Treatment Market In its latest report, Fact.MR offers unbiased analysis of the global mosquito-borne diseases treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of disease type (bacterial infection, parasitic infection, viral infection) drug type (antibiotic drugs, antiviral drugs, analgesic drugs, anti-pyretic drugs, non-steroidal anti-inflammatory drugs) and distribution channel (retail pharmacies, hospital pharmacies, online pharmacies, and drug stores) across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa) Request more information about Report Methodology Explore Fact.MR’s Coverage on the Healthcare Domain PCR and Real-time PCR Molecular Diagnostics Market: A recent study by Fact.MR on the PCR and real-time molecular diagnostics market offers a 10-year forecast for 2020 to 2030. The study analyzes key trends that are currently determining the growth of the market. This report covers vital dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players. Actigraphy Sensors Market: Fact.MR’s extensive coverage on the actigraphy sensors market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the landscape. Breathalyzer Market: The global breathalyzer market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in forthcoming years. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583